Outcomes and clinical characteristics of the compassionate use of plitidepsin for immunocompromised adult patients with COVID-19-Reference-Cited by-同舟云学术

Outcomes and clinical characteristics of the compassionate use of plitidepsin for immunocompromised adult patients with COVID-19

Published:2023-10 Issue: Volume:135 Page:12-17
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Aguareles José^ORCID,Fernández Paula Villares,Carralón-González María Maravillas,Izquierdo Carles Forné^ORCID,Martí-Ballesteros Eva María,Fernández Virginia Pradillo,Sotres-Fernandez Gabriel,García-Delangue Teresa,LaPetra Rocío García de Viedma,Sánchez-Manzano María Dolores,Gutiérrez Carolina,García-Coca Marta^ORCID,Carnevali-Ruiz Daniel,Barrena-Puertas Ruth,Luque-Pinilla José Manuel,Lloris Raquel,Luepke-Estefan Xavier Erik^ORCID,López-Martín José Antonio,Jimeno José María,Guisado-Vasco Pablo^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference14 articles.

1. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19 – COVID-NET, 10 states, March 2020–February 2022;Singson;MMWR Morb Mortal Wkly Rep,2022

2. Characteristics associated with the residual risk of severe COVID-19 after a complete vaccination schedule: a cohort study of 28 million people in France;Semenzato;Lancet Reg Health Eur,2022

3. Dexamethasone in hospitalized patients with Covid-19;Collaborative Group;N Engl J Med,2021

4. Improving the outcomes of immunocompromised patients with coronavirus disease 2019;Haidar;Clin Infect Dis,2021

5. Drivers of adaptive evolution during chronic SARS-CoV-2 infections;Harari;Nat Med,2022